Top-line Results: QTORIN Rapamycin Hits Primary Endpoint in Phase 3 Microcystic LM Trial

Once-daily QTORIN 3.9% rapamycin anhydrous gel produced a statistically significant improvement in microcystic lymphatic malformations (microcystic LMs), according to results from the SELVA Phase 3 trial.